MY006
/ Mabylon
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 10, 2026
MY006, a half-life extended trispecific IgG4 antibody for the prevention of allergic reactions to peanut
(AAAAI 2026)
- "Conclusions MY006 is being developed as a novel alternative to desensitization approaches, with the potential to offer peanut allergic patients long-lasting protection without allergen exposure, with an expected dosing of only few subcutaneous injections per year, owing to half-life extension, mechanism of action, and potency. MY006 is currently being evaluated in the clinics as a promising option for patients with severe peanut allergies."
Trispecific • Allergy • Food Hypersensitivity • Immunology
December 31, 2025
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Mabylon AG | Not yet recruiting ➔ Recruiting
Enrollment open • Allergy • Food Hypersensitivity • Immunology
December 17, 2025
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
(clinicaltrials.gov)
- P1 | N=48 | Not yet recruiting | Sponsor: Mabylon AG
New P1 trial • Allergy • Food Hypersensitivity • Immunology
1 to 3
Of
3
Go to page
1